Daily Stock Analysis, CPHI, China Pharma Holdings Inc, priceseries

China Pharma Holdings Inc. Daily Stock Analysis
Stock Information
Open
0.29
Close
0.27
High
0.29
Low
0.26
Previous Close
0.26
Daily Price Gain
0.01
YTD High
0.58
YTD High Date
Apr 4, 2019
YTD Low
0.21
YTD Low Date
Jan 3, 2019
YTD Price Change
0.03
YTD Gain
11.92%
52 Week High
0.84
52 Week High Date
Oct 18, 2018
52 Week Low
0.19
52 Week Low Date
Sep 18, 2018
52 Week Price Change
0.04
52 Week Gain
16.78%
Company Information
Stock Symbol
CPHI
Exchange
NYSE MKT
Company URL
http://www.chinapharmaholdings.com
Company Phone
8689866811730
CEO
Zhi Lin Li
Headquarters
-
Business Address
2ND FLOOR, NO. 17, JINPAN ROAD, HAIKOU, HAINAN PROVINCE, CHINA 570216
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001106644
About

China Pharma Holdings, Inc. engages in the development, manufacture, and market of pharmaceutical products for human use in connection with a variety of high incidence and high morality diseases and medical conditions. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China

Description

China Pharma Holdings, Inc., together with its subsidiaries, develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. It offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions, and granules. The company's products are used for the treatment of central nervous system and cerebral-cardiovascular, anti-infection and respiratory, and digestive and other diseases. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and surgery-thrombus deep phlebitis; and Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and lipoprotein blood diseases. The company also provides Bumetanide to treat edema diseases; Candesartan for hypertension; Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Anhydroandrographolide for ischemic heart, cerebrovascular, and lipoprotein blood diseases; and Clarithromycin granules and capsules. In addition, it offers Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release tablets that provide relief from cold, sinus, and flu symptoms; Gull Wood extract syrup; Hepatocyte growth-promoting factor; Tiopronin; Compound Ammonium Glycyrrhetate S; Omeparzole; Vitamin B6; and Granisetron Hydrochloride injection. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.